SNT
data caveat$54M11mo
Syntara
Biotech · Haematology
Clinical-stage company targeting extracellular matrix dysfunction with amine oxidase chemistry, focused on therapies for myelofibrosis and MDS.
Data HealthTrials1 of 1 active · stale enrollment
Cash data from Dec 2025 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$10.5M
Dec 2025 4C
Runway
11moCAUTION
Based on Dec 2025 4C
Market Cap
$54M
Burn Rate
$2.8M/qtr
Dec 2025 4C
Shares Outstanding
1.6B
Pipeline Assets
3
3M Price
SNT.ASX$0.033-8.3% 3M
Low $0.029High $0.036
Pipeline Assets (3)
SNT-5505 (amsulostat)Myelodysplastic syndromes (high-risk)
Phase 1/2SNT-5505 (amsulostat)Myelofibrosis
Phase 2SNT-5505 (amsulostat)Myelodysplastic syndromes (low-risk)
Phase 2Discovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Short Interest
ASIC ↗as of 2026-04-17 · 4-day lag
Short position
0.11%
Shares short
1.8M
Aggregated short position data published by ASIC under the Corporations Act. T+4 reporting lag applies. Short interest ≥5% is noteworthy; ≥10% is elevated. Source: ASIC Short Selling Data
Competitive Landscape
4 approved drugs202 competitor trialsPhase 2+ · Non-ASX
Myelodysplastic Syndromes (High-Risk)86 active trials
5 Ph31 Ph2/351 Ph229 Ph1/PHASE2
Myelodysplastic Syndromes (Low-Risk)37 active trials
1 Ph47 Ph32 Ph2/323 Ph24 Ph1/PHASE2
Competitor trials from ClinicalTrials.gov (Phase 2+ historical, Phase 3+ refreshed weekly, active/recruiting, non-ASX sponsors). Approved drugs from OpenFDA (NDA/BLA only). Updated weekly via fetch_competitors.py.
expand_moreClinical Publications
Peer-reviewed papers & conference abstracts via PubMed
4 papers
Clinical Publications
Peer-reviewed papers & conference abstracts via PubMed
Cancer Res2026-02
Haematologica2025-10
Sci Transl Med2025-09
Catalysts (8)· 5 upcoming · 3 past
FDA feedback on myelofibrosis development plan
UpcomingExpectedarrow_upwardHigh30 June 2026
EMA Orphan Drug Designation decision (MF)
UpcomingExpectedremoveMed30 June 2026
Phase 2 MF combo (ruxolitinib) efficacy data readout
UpcomingExpectedarrow_upwardHigh30 June 2026
AZALOX interim data (high-risk MDS/CMML)
UpcomingDelivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Delivery Consistency Index
Delivery
–Insufficient data
0/3 data points needed
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
–Insufficient data
1/2 data points needed
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
Clinical Trials(7)
1 activeClinicalTrials.gov ↗
Ph2Active Not RecruitingEnrollment stale · 900d
PXS-4728 (A)Matching Placebo (B)
Effect of PXS-4728A on Microglia Activation in Participants With Isolated Rapid Eye Movement Sleep Behaviour Disorder
REM Sleep Behavior Disorder
RandomizedQuadruple Blind50 Years – 80 Years
Primary endpoint To assess the reduction of microglial activation across striato-cortical regions